Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Earlier this year, the company also reported positive results from the FLOW trial of semaglutide in patients with type 2 diabetes and CKD, showing that it slashed the risk of major cardiovascular ...

As tools become more precise and non-invasive, doctors are able to diagnose and treat heart conditions with greater accuracy and efficiency.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Semaglutide, used for diabetes and obesity, may reduce alcohol cravings in adults with alcohol use disorder, offering a potential solution to a major treatment gap.

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...